The DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.
Clinical Acquired Resistance to KRASG12C Inhibition through a Novel KRAS Switch-II Pocket Mutation and Polyclonal Alterations Converging on RAS–MAPK Reactivation
Open accessPublished version of a preprint
Abstract
Mutant-selective KRASG12C inhibitors, such as MRTX849 (adagrasib) and AMG 510 (sotorasib), have demonstrated efficacy in KRASG12C-mutant cancers, including non–small cell lung cancer (NSCLC). However, mechanisms underlying clinical acquired resistance to KRASG12C inhibitors remain undetermined. To begin to define the mechanistic spectrum of acquired resistance, we describe a patient with KRASG12C NSCLC who developed polyclonal acquired resistance to MRTX849 with the emergence of 10 heterogeneous resistance alterations in serial cell-free DNA spanning four genes (KRAS, NRAS, BRAF, MAP2K1), all of which converge to reactivate RAS–MAPK signaling. Notably, a novel KRASY96D mutation affecting the switch-II pocket, to which MRTX849 and other inactive-state inhibitors bind, was identified that interferes with key protein–drug interactions and confers resistance to these inhibitors in engineered and patient-derived KRASG12C cancer models. Interestingly, a novel, functionally distinct tricomplex KRASG12C active-state inhibitor RM-018 retained the ability to bind and inhibit KRASG12C/Y96D and could overcome resistance. Significance: In one of the first reports of clinical acquired resistance to KRASG12C inhibitors, our data suggest polyclonal RAS–MAPK reactivation as a central resistance mechanism. We also identify a novel KRAS switch-II pocket mutation that impairs binding and drives resistance to inactive-state inhibitors but is surmountable by a functionally distinct KRASG12C inhibitor. See related commentary by Pinnelli and Trusolino, p. 1874. This article is highlighted in the In This Issue feature, p. 1861
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Acquired mutations of NRAS, BRAF, RTK, and MYC were also found in patients treated with sotorasib or adagrasib monotherapy [49, 51, 53, 54].”
From Differential Response and Resistance to KRAS-Targeted Therapy (2025) · cites this paper as [54]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Point mutations in the KRAS gene included G12D/F/R/V/W, which prevent covalent interactions with mutant cysteine, as well as V8L, G13D, V14I, Q61H, H95D/Q/R, Y96C, and Y96D [62,97,102,103].”
From KRAS: Biology, Inhibition, and Mechanisms of Inhibitor Resistance (2024) · cites this paper as [103]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Multiple mechanisms of acquired resistance have been identified, which largely converge on re-activation of the RAS pathway or alternatively activate parallel signaling pathways such as the PI3K/mTOR pathway10–14.”
From Combined inhibition of KRASG12C and mTORC1 kinase is synergistic in non-small cell lung cancer (2024) · cites this paper as [13]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“We and others have recently described mechanisms of acquired resistance in patients with lung and colorectal cancer (CRC) treated with KRASG12C inhibitors, including mutations in KRAS or other RTK–RAS–MAPK pathway effectors, adaptive signaling alterations, and histologic transformation to drug-resistant cell states (14, 18–24).”
From Mechanisms of Resistance to Oncogenic KRAS Inhibition in Pancreatic Cancer (2024) · cites this paper as [20]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Vertical reactivation of the RAS pathway elements has been observed in most samples collected from patients who developed resistance to KRASG12C inhibitors.4,8,20,21”
From Therapeutic targeting of syndecan-1 axis overcomes acquired resistance to KRAS-targeted therapy in gastrointestinal cancers (2025) · cites this paper as [20]
Experimental — accuracy not yet measured
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Genetic alterations, especially secondary RAS mutations, have been identified as one of the most common mechanisms of acquired resistance to KRAS inhibitors in patients [49, 51–55].”
From Differential Response and Resistance to KRAS-Targeted Therapy (2025) · cites this paper as [54]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“In recent work, a case was described of an acquired Y96D switch II pocket mutation identified at a low variant allele frequency in ctDNA at the time of acquired resistance to adagrasib.23”
From Acquired Resistance to KRAS G12C Inhibition in Cancer (2021) · cites this paper as [23]
The cited source says what the claim attributes to it.
In the citing paper
“Many of the novel mutations were observed at low subclonal frequencies, contributing to tumor heterogeneity [97,103].”
From KRAS: Biology, Inhibition, and Mechanisms of Inhibitor Resistance (2024) · cites this paper as [103]
The cited source says what the claim attributes to it.
In the citing paper
“While previous studies have characterized acquired resistance to KRASG12C inhibition and identified causal mutations and non-genetic mechanisms including RTK activation and epithelial-to-mesenchymal transition11–14,35, the mechanisms underlying differential sensitivity to KRASG12C inhibition are less well understood.”
From Combined inhibition of KRASG12C and mTORC1 kinase is synergistic in non-small cell lung cancer (2024) · cites this paper as [13]
The cited source says what the claim attributes to it.
In the citing paper
“The genetic alterations identified in these studies are highly heterogeneous and may mediate therapeutic resistance via diverse mechanisms, such as changing inhibitor binding affinity, reactivating KRAS activity, and bypassing KRAS-mediated signaling [54, 56].”
From Differential Response and Resistance to KRAS-Targeted Therapy (2025) · cites this paper as [54]
The cited source says what the claim attributes to it.
In the citing paper
“Prior studies indicated that tumors with acquired resistance to KRASG12C agents can have multiple resistance mechanisms, including alterations within the RAS/MAPK pathway and bypass activating alterations”
From Bcl-xL Is a Key Mediator of Apoptosis Following KRASG12C Inhibition in KRASG12C -mutant Colorectal Cancer (2023) · cites this paper as [29]
In the citing paper
“RM-018 (13), developed by Revolution Medicines, covalently binds to the activated state of KRASG12C mutants, forms a ternary complex with cyclophilin A and KRASG12C, thereby inhibiting their activity.”
From Recent advances in targeting the “undruggable” proteins: from drug discovery to clinical trials (2023) · cites this paper as [81]
In the citing paper
“Meanwhile, RM-018 retained the ability to bind and inhibit KRASG12C/Y96D, thus overcoming drug resistance.81”
From Recent advances in targeting the “undruggable” proteins: from drug discovery to clinical trials (2023) · cites this paper as [81]
In the citing paper
“Adagrasib is a selective and irreversible oral small-molecule inhibitor of the mutant KRAS G12C protein18 and was recently approved by the FDA for treatment of NSCLC who have received at least 1 prior systemic therapy19.”
From Early Changes in Circulating Cell-Free KRAS G12C Predict Response to Adagrasib in KRAS Mutant Non–Small Cell Lung Cancer Patients (2023) · cites this paper as [18]
In the citing paper
“Nonetheless, there remains an ongoing need for improved clinical outcomes (21), especially since emerging data indicate multiple mechanisms of acquired resistance in patients treated with sotorasib or adagrasib (22–24), many of which involve RAS pathway reactivation.”
In the citing paper
“acquired second-site Y96D mutations in KRASG12C confer clinical resistance to adagrasib by altering the switch 2 pocket such that the inhibitor can no longer bind69.”
From The current state of the art and future trends in RAS-targeted cancer therapies (2022) · cites this paper as [69]
In the citing paper
“For example, RM-018 is a covalent KRASG12C inhibitor, but through its interaction with cyclophilin A, targets KRASG12C in the GTP-bound state; hence, RM-018 is a KRASG12C-on inhibitor69.”
From The current state of the art and future trends in RAS-targeted cancer therapies (2022) · cites this paper as [69]
In the citing paper
“Pan-KRAS drugs would have advantages versus mutant-selective KRAS drugs in heterogeneous cancers driven by multiple KRAS alterations at baseline or upon development of acquired resistance due to secondary KRAS on-target alterations when compared to mutant-selective inhibitors (Fig. 3), with first examples emerging in the clinic (64–66).”
From Expanding the Reach of Precision Oncology by Drugging All KRAS Mutants (2022) · cites this paper as [65]
In the citing paper
“This has been shown preclinically with the tricomplex KRASG12C active state inhibitor RM-018 in cellular models expressing a KRASG12C Y96D double mutant variant (65).”
From Expanding the Reach of Precision Oncology by Drugging All KRAS Mutants (2022) · cites this paper as [65]
In the citing paper
“Preclinical and clinical data suggest that resistance to KRAS p.G12C inhibition is dependent on receptor tyrosine kinase activity, especially epidermal growth factor receptor (EGFR)-signalling.29 31 32”
From Current and emerging concepts for systemic treatment of metastatic colorectal cancer (2025) · cites this paper as [32]
In the citing paper
“correlative studies conducted in other KRASG12C-mutant tumor types treated with these inhibitors have demonstrated the emergence of pleiotropic resistance through both cell autonomous and non-cell autonomous mechanisms76–78.”
From Pancreatic cancer: Advances and challenges (2023) · cites this paper as [77]
In the citing paper
“Thereby, KRAS (Y96D) conferred resistance to KRAS (G12C) inhibitors in patient-derived KRAS (G12C) xenografts [96].”
From Targeting KRAS mutant cancers: from druggable therapy to drug resistance (2022) · cites this paper as [96]
In the citing paper
“RM-018, a neoteric KRAS (G12C) active state inhibitor, retains the ability to inhibit KRAS (G12C/Y96D) and may address the problem of drug resistance [96].”
From Targeting KRAS mutant cancers: from druggable therapy to drug resistance (2022) · cites this paper as [96]
In the citing paper
“Recently, a novel KRAS (Y96D) mutation was found, which affects the switch-II pocket and reduces the H-bonding between the Y96 residue of KRAS and MRTX849.”
From Targeting KRAS mutant cancers: from druggable therapy to drug resistance (2022) · cites this paper as [96]
In the citing paper
“It binds cyclophilin A, and this binary complex can associate with the active state of KRAS G12C and form a covalent bond.”
From Chasing molecular glue degraders: screening approaches (2022) · cites this paper as [113]
In the citing paper
“Interestingly, KRAS Y96D confers resistance to currently approved (non-gluelike) covalent KRAS G12C inhibitors, and RM-018 overcomes such KRAS G12C/Y96D -mediated resistance.”
From Chasing molecular glue degraders: screening approaches (2022) · cites this paper as [113]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Berman, H. M. (2000) · Nucleic Acids Research · doi:10.1093/nar/28.1.235 · Cited by 40,196
K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions
Ostrem, J. M., Peters, U., Sos, M. L., Wells, J. A., & Shokat, K. M. (2013) · Nature · doi:10.1038/nature12796 · Cited by 2,557
The Clinical KRAS(G12C) Inhibitor AMG 510 Drives Anti-Tumour Immunity
Canon, J., Rex, K., Saiki, A. Y., Mohr, C., Cooke, K., Bagal, D., Gaida, K., Holt, T., Knutson, C. G., Koppada, N., et al. (2019) · Nature · doi:10.1038/s41586-019-1694-1 · Cited by 2,277
AACR Project GENIE: Powering Precision Medicine through an International Consortium
The AACR Project GENIE Consortium, The AACR Project GENIE Consortium, André, F., Arnedos, M., Baras, A. S., Baselga, J., Bedard, P. L., Berger, M. F., Bierkens, M., Calvo, F., et al. (2017) · Cancer Discovery · doi:10.1158/2159-8290.cd-17-0151 · Cited by 1,964
KRAS G12C Inhibition with Sotorasib in Advanced Solid Tumors
Hong, D. S., Fakih, M. G., Strickler, J. H., Desai, J., Durm, G. A., Shapiro, G. I., Falchook, G. S., Price, T. J., Sacher, A., Denlinger, C. S., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa1917239 · Cited by 1,733
The COSMIC Cancer Gene Census: describing genetic dysfunction across all human cancers
Sondka, Z., Bamford, S., Cole, C. G., Ward, S. A., Dunham, I., & Forbes, S. A. (2018) · Nature Reviews Cancer · doi:10.1038/s41568-018-0060-1 · Cited by 1,597
Hallin, J., Engstrom, L. D., Hargis, L., Calinisan, A., Aranda, R., Briere, D. M., Sudhakar, N., Bowcut, V., Baer, B. R., Ballard, J. A., et al. (2020) · Cancer Discovery · doi:10.1158/2159-8290.cd-19-1167 · Cited by 1,304
Targeting KRAS mutant cancers with a covalent G12C-specific inhibitor
Janes, M. R., Zhang, J., Li, L.-S., Hansen, R., Peters, U., Guo, X., Chen, Y., Babbar, A., Firdaus, S. J., Darjania, L., et al. (2018) · Cell · doi:10.1016/j.cell.2018.01.006 · Cited by 1,172
Self-citationAnchored multiplex PCR for targeted next-generation sequencing
Zheng, Z., Liebers, M. R., Zhelyazkova, B. H., Cao, Y., Panditi, D., Lynch, K. D., Chen, J., Robinson, H. E., Shim, H. S., Chmielecki, J., et al. (2014) · Nature Medicine · doi:10.1038/nm.3729 · Cited by 913
Discovery of a Covalent Inhibitor of KRAS G12C (AMG 510) for the Treatment of Solid Tumors
Lanman, B. A., Allen, J. R., Allen, J. G., Amegadzie, A. K., Ashton, K. S., Booker, S. K., Chen, J. J., Chen, N., Frohn, M. J., Goodman, G., et al. (2020) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.9b01180 · Cited by 765
Cited by
Sorted by citations
Items 301–400 of 529
Qing, L., Cheng, Z., Xu, J., Wang, Z., Li, Y., Gauthier, M., Zhang, S., & He, H. (2024) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2024.117065 · Cited by 6
Principe, D. R., Becker, J. H., Metropulos, A. E., Marinelarena, A. M., Pham, T. D., Aissa, A. F., & Munshi, H. G. (2026) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-25-0483 · Cited by 6
Huang, R., Gong, X., Du, J., Xu, G., Qian, J., Liao, G., Lin, Y., Pan, M., Zheng, B., Yuan, W., et al. (2026) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1704347 · Cited by 6
Wei, X., Blaj, C., Al-Radhawi, M. A., Lai, L., Maldonato, B. J., Yang, Y. C., Seu, L., Gundlapalli, H., Jiang, L., Ayala, M. A. M., et al. (2026) · Cancer Discovery · doi:10.1158/2159-8290.cd-25-1616 · Cited by 6
Lin, Q., Morales-Giron, A. A., Sander, C., Curtis, J. M., Barnes, H., Patel, P. S., de la Cruz, F. F., Riedl, J. M., Matsubara, H., Nakamura, H., et al. (2026) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-25-1788 · Cited by 6
Self-citationAlisertib exerts KRAS allele‑specific anticancer effects on colorectal cancer cell lines
Ren, B., 高卓维, Zheng, K., Yang, Y., Su, P., Luo, Q., Feng, J., Zhentao, L., Geng, Y., Ju, Y., et al. (2023) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2023.11942 · Cited by 6
Park, S. L., Saralamma, V. V. G., Nale, S. D., Kim, C. J., Jo, Y. S., Baig, M. H., & Cho, J. (2024) · Heliyon · doi:10.1016/j.heliyon.2024.e28495 · Cited by 6
Sequence-defined phosphoestamers for selective inhibition of the KRAS G12D /RAF1 interaction
Claringbold, B., Vance, S., Paul, A. R., Williamson, J., Garrett, M. D., & Serpell, C. J. (2024) · Chemical Science · doi:10.1039/d4sc07218a · Cited by 6
YB-1 activating cascades as potential targets in KRAS-mutated tumors
Khozooei, S., Veerappan, S., & Toulany, M. (2023) · Strahlentherapie und Onkologie · doi:10.1007/s00066-023-02092-8 · Cited by 6
Oncogenic dependency plays a dominant role in the immune response to cancer
Li, J., D’Amico, S., Kirillov, V., Petrenko, O., & Reich, N. C. (2023) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2308635120 · Cited by 6
PROTACs in gynecological cancers: Current knowledge and future potential as a treatment strategy
Movahed, F., Ourang, Z., Neshat, R., Hussein, W. S., Saihood, A. S., Alarajy, M. S., & Zareii, D. (2024) · Pathology - Research and Practice · doi:10.1016/j.prp.2024.155611 · Cited by 7
Combinatorial approaches for mitigating resistance to KRAS-targeted therapies
Warren, H. R., Ross, S. J., Smith, P. D., Coulson, J. M., & Prior, I. A. (2022) · Biochemical Journal · doi:10.1042/bcj20220440 · Cited by 6
Ongoing and evolving clinical trials enhancing future colorectal cancer treatment strategies
Ros, J., Gonzalez, N. S., Salvà, F., Baraibar, I., Alonso, G., Tabernero, J. M., & Élez, E. (2022) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2022.2040016 · Cited by 6
Mechanisms and current advances in treating KRAS-mutated lung cancer
Chao, C. H.-Y., & Di, Y. P. (2025) · Chinese Medical Journal - Pulmonary and Critical Care Medicine · doi:10.1016/j.pccm.2025.08.001 · Cited by 6
Emerging therapeutic advancements in pancreatic cancer: a contemporary review
Malla, M., Sakr, Y., Gupta, G., Akce, M., & El‐Rayes, B. F. (2025) · Discover Oncology · doi:10.1007/s12672-025-03027-8 · Cited by 6
GAP mimetic activity of pan-Ras TCI daraxonrasib synergizes with K-Ras Switch-II pocket inhibition
Pfaff, P., & Shokat, K. M. (2026) · Biological Chemistry · doi:10.1515/hsz-2025-0249 · Cited by 5
Foth, M., Kim, W., O’Toole, K. T., Murphy, B., Justo-Garrido, M., Boggaram, S. S., Ghazi, P. C., Brennan, E., Wright, M. I., Shepherd, T., et al. (2026) · Cancer Research · doi:10.1158/0008-5472.can-26-1313 · Cited by 5
Farnesylation-driven KRAS phase separation promotes colon tumor growth
Wang, X., Zhang, Y., Lu, M., Gong, Y., Guan, T., Hou, G., Wei, Y., Wang, M., Liu, H., Huang, L., et al. (2026) · Cell · doi:10.1016/j.cell.2026.05.002 · Cited by 5
Rosas, D., Barad, P., Wright, J., & Raez, L. E. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27146455 · Cited by 5
Advances in KRAS mutation inhibition in metastatic colorectal cancer
Wu, C., Li, W., Chen, M., Zhang, Q., Xu, T., Ma, Y., Liu, W., Wang, Z., Wang, X., Li, J., et al. (2023) · Holistic Integrative Oncology · doi:10.1007/s44178-023-00032-1 · Cited by 5
KRAS and NRAS Translation Is Increased upon MEK Inhibitors-Induced Processing Bodies Dissolution
Vidal-Cruchez, O., Nicolini, V. J., Rete, T., Rezzonico, R., Lacoux, C., Fassy, J., Jacquet, K., Roméo, B., Ventujol, C., Hubstenberger, A., et al. (2023) · Cancers · doi:10.3390/cancers15123078 · Cited by 7
Lee, A. T., & Nagasaka, M. (2024) · Lung Cancer Targets and Therapy · doi:10.2147/lctt.s492126 · Cited by 5
Recent advances in targeted degradation in the RAS pathway
Ge, Z., Fan, Z., He, W., Zhou, G., Zhou, Y., Zheng, M., & Zhang, S. (2025) · Future Medicinal Chemistry · doi:10.1080/17568919.2025.2476387 · Cited by 6
Li, R., Huang, X., Wang, R., Ren, Z., Zhu, Y. L., Lu, T., Sun, Y., & Hao, C. (2025) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2025.117718 · Cited by 6
Evolution of structure-guided drug design strategies targeting mutations in codon 12 of KRAS
Dorandish, S., Bhayekar, K., Singh, A., Kushwaha, N. D., Malin, E., Serafimovski, S., Kelm, J. M., Gavande, N. S., & Lakkaniga, N. R. (2025) · RSC Medicinal Chemistry · doi:10.1039/d5md00169b · Cited by 6
Zhang, J., Zhang, K., Li, J., Zhang, J., & Cui, X. (2024) · Cellular and Molecular Biology · doi:10.14715/cmb/2024.70.1.9 · Cited by 5
Self-citationKRAS G12C Inhibitors in the Treatment of Metastatic Colorectal Cancer
Xiao, A., & Fakih, M. (2024) · Clinical Colorectal Cancer · doi:10.1016/j.clcc.2024.05.004 · Cited by 5
Targeting active RAS with molecular glue
Su, W., & Hou, X. (2024) · Pharmaceutical Science Advances · doi:10.1016/j.pscia.2024.100047 · Cited by 5
Li, K., Huo, Q., Li, B., & Yokota, H. (2023) · Proteomes · doi:10.3390/proteomes11010005 · Cited by 5
Zhang, J., Zhang, J., Leung, E. L., & Yao, X. (2023) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2023.2178419 · Cited by 5
Self-citationUnderstanding and drugging RAS: 40 years to break the tip of the iceberg
Brady, D. C., Hmeljak, J., & Dar, A. C. (2022) · Disease Models & Mechanisms · doi:10.1242/dmm.049519 · Cited by 5
Line by Line: Distinct Patterns of Anti-EGFR Antibody Resistance by Line of Therapy
Corcoran, R. B. (2022) · Journal of Clinical Oncology · doi:10.1200/jco.22.01922 · Cited by 5
Self-citationConvergence of Targeted and Immune Therapies for the Treatment of Oncogene-Driven Cancers
Cox, A. D., Ting, J. P. ‐., & Der, C. J. (2023) · Cancer Discovery · doi:10.1158/2159-8290.cd-22-1199 · Cited by 5
Preclinical Modeling of Pathway-Targeted Therapy of Human Lung Cancer in the MousePreprint
Vaishnavi, A., Kinsey, C. G., & McMahon, M. (2023) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a041385 · Cited by 5
Discovery of RMC-6291, a potent, orally bioavailable, covalent RAS(ON) G12C selective inhibitor
Cregg, J., Pota, K., Gill, A. L., & Koltun, E. S. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-21861-3.00006-1 · Cited by 4
The RAS Signaling Network and Cancer
Hibshman, P. S., & Der, C. J. (2024) · Springer eBooks · doi:10.1007/978-3-031-62945-7_17 · Cited by 4
Mateo-Victoriano, B., Samaranayake, G. J., Pokharel, S. P., Sahayanathan, G. J., Jayaraj, C. J., Troccoli, C. I., Watson, D. C., Mohsen, M. G., Guo, Y., Kool, E. T., et al. (2025) · Redox Biology · doi:10.1016/j.redox.2025.103610 · Cited by 4
Sarıca, Z., Kürkçüoğlu, Ö., & Sungur, F. A. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26073293 · Cited by 4
Escher, T. E., Yuk, S. A., Yuan, Q., Qiang, W., Almunif, S., Sharma, S., Scott, E. A., & Satchell, K. J. F. (2025) · ACS Applied Bio Materials · doi:10.1021/acsabm.5c00179 · Cited by 4
Anticancer activity of RAS-GTP inhibition in cholangiocarcinoma
Entrialgo‐Cadierno, R., Morali, K., Feliu, I., Wang, Y., Evans, J., Yáñez-Bartolomé, M., López, I., Macaya, I., Cueto‐Ureña, C., Sin-Coscujuela, D., et al. (2026) · Cancer Cell · doi:10.1016/j.ccell.2026.03.020 · Cited by 4
Aust, O., Thiel, M. R. T., Blanc, E., Lüthen, M., Hollek, V., Astaburuaga-García, R., Klinger, B., Böhning, F., Trinks, A., Beule, D., et al. (2025) · Science Signaling · doi:10.1126/scisignal.adr3738 · Cited by 5
Lu, H. J., Fu, W., Xia, Y., Yan, Y., Shu, C.-H., Chen, Y., Xu, C., Zheng, P., Shen, X., Cui, R., et al. (2025) · Cell Death Discovery · doi:10.1038/s41420-025-02657-9 · Cited by 4
Advances on drug therapy for KRAS-mutant non-small-cell lung cancer
Tian, T., & Li, W. (2026) · Translational Oncology · doi:10.1016/j.tranon.2026.102668 · Cited by 4
Treating Pancreatic Ductal Adenocarcinoma: The Targeted Revolution is Here
May, M. S., Park, W., & O'Reilly, E. M. (2026) · Drugs · doi:10.1007/s40265-026-02295-0 · Cited by 4
PI3K Regulates Wild-type RAS Signaling to Confer Resistance to KRAS Inhibition
Ge, X., Singh, J., Li, W., Bishop, C. S., Ruiz, C. F., Stites, E. C., Bhattacharyya, M., Liu, Y., & Muzumdar, M. D. (2026) · Cancer Research · doi:10.1158/0008-5472.can-25-3625 · Cited by 4
microRNA-203 functions as a natural Ras inhibitor in hepatocellular carcinoma.
Guo, J., Li, L., Deng, N., Xu, Y. X., Wang, G., Luo, H. R., Xu, C., & Li, X. (2023) · PubMed Central · Cited by 4
A Nexus between Genetic and Non-Genetic Mechanisms Guides KRAS Inhibitor Resistance in Lung Cancer
Kulkarni, P., Mohanty, A. R., Ramisetty, S. K., Duvivier, H. L., Khan, A., Shrestha, S., Tan, T., Merla, A., El-Hajjaoui, M., Malhotra, J. D., et al. (2023) · Biomolecules · doi:10.3390/biom13111587 · Cited by 4
The Potential Treatment Options and Combination Strategies of KRAS-Mutated Lung Cancer
Zhao, X., Zheng, Y., Wang, Y., Zhang, M., Dong, Z., Liu, Y., & Sun, M. (2024) · OncoTargets and Therapy · doi:10.2147/ott.s484209 · Cited by 4
Chen, S., Dong, R., Li, Y., Zheng, N., Peng, G., Lu, F., Qiu, Q., Wen, H., Wang, Y., Wu, H., et al. (2022) · Frontiers in Genetics · doi:10.3389/fgene.2022.918159 · Cited by 4
Mullaguri, S. C., Akula, S., Sahoo, P. S., Ashireddygari, V. R., Mupparapu, V., Silveri, R., Burra, P. V. L. S., & Kancha, R. K. (2022) · 3 Biotech · doi:10.1007/s13205-022-03407-9 · Cited by 4
Characterization of 164 patients with NRAS mutated non-small cell lung cancer (NSCLC)
Dehem, A., Mazières, J., Chour, A., Guisier, F., Ferreira, M., Boussageon, M., Girard, N., Moro‐Sibilot, D., Cadranel, J. L., Zalcman, G., et al. (2023) · Lung Cancer · doi:10.1016/j.lungcan.2023.107393 · Cited by 4
Chemical synthesis as a discovery platform in immunosuppression and determination of mode of action
Schupp, M., Saridakis, I., Kaiser, D., & Maulide, N. (2024) · Nature Synthesis · doi:10.1038/s44160-023-00423-2 · Cited by 4
Carrascosa, J. M., Aterido, A., Li, T., Guillén, Y., Martinez, S., Marsal, S., & Julià, A. (2023) · Actas Dermo-Sifiliográficas · doi:10.1016/j.ad.2023.10.032 · Cited by 4
Engineered protein circuits for cancer therapyPreprint
Lu, A. C., Moeller, L., Moore, S., Ho, K., Tobin, V., Qiang, A., Zhang, E., Li, Z., Wang, M., Xia, S., et al. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.04.16.647665 · Cited by 5
EGFR blockade confers sensitivity to pan-RAS inhibitors in KRAS-mutated cancers
Han, J., Yu, B., Jing, J., He, X., Hua, Y., & Xu, G. (2025) · Cellular Oncology · doi:10.1007/s13402-025-01075-4 · Cited by 3
Abdollahi, A., Favata, M. F., Weber, M., Roman, V. D., Hess, R., Hammond, K., Farren, M. R., Schaffer, M., Gilmartin, A. G., Wang, H., et al. (2025) · PLoS ONE · doi:10.1371/journal.pone.0327588 · Cited by 3
Riedel, R. F., Ruge, L., Verheyen, M., John, F., Scharpenseel, H., Nogová, L., Michels, S. Y. F., Fischer, R. N., Eisert, A., Jakob, C. E. M., et al. (2025) · JTO Clinical and Research Reports · doi:10.1016/j.jtocrr.2025.100925 · Cited by 3
Shen, T., Fei, W., Hu, Z., Pang, M., Ma, J., Zhou, T., & Shang, Y. (2025) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2025.109345 · Cited by 3
Systematic and precise interventions for KRAS-mutant cancers
Liang, J., Wu, J., Zhang, Y., Wang, H., Zheng, Y., & He, Q. (2026) · Experimental Hematology and Oncology · doi:10.1186/s40164-026-00763-7 · Cited by 4
Luna-Ramírez, L., García‐Navas, R., Santos, E., & Baltanás, F. C. (2026) · Molecular Cancer · doi:10.1186/s12943-026-02632-7 · Cited by 3
Kamel, E. M., Khadrawy, S. M., Ali, M. A. M., Abukhadra, M. R., Yassin, N. Y. S., Alkhedhairi, S., Alkhayl, F. F. A., & Lamsabhi, A. M. (2026) · Frontiers in Chemistry · doi:10.3389/fchem.2026.1808601 · Cited by 3
Martín, A., García-Pérez, I. M., José, S. S., Rojo, P., Riego‐Mejías, C., Teodósio, C., Barbosa, B. M. G., Sánchez, C., Folch-I-Casanovas, I., Odena, M. A., et al. (2026) · Cancer Research · doi:10.1158/0008-5472.can-25-5172 · Cited by 3
Rekowska, A. K., Rola, P., Kwiatkowska, A., Wójcik-Superczyńska, M., Gil, M., Krawczyk, P. A., & Milanowski, J. (2024) · Biomedicines · doi:10.3390/biomedicines12020325 · Cited by 3
Bağcı, Ö. (2024) · Biology of the Cell · doi:10.1111/boc.202400017 · Cited by 3
Cregg, J., Edwards, A. V., Tomlinson, A. C. A., Gill, A. L., & Koltun, E. S. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-21861-3.00011-5 · Cited by 3
Unraveling (K)RAS in pancreatic ductal adenocarcinoma
Doleschal, B. (2024) · memo - Magazine of European Medical Oncology · doi:10.1007/s12254-024-01003-6 · Cited by 3
Intratumor heterogeneity in KRAS signaling shapes treatment resistance
Petrenko, O., Kirillov, V., D’Amico, S., & Reich, N. C. (2024) · iScience · doi:10.1016/j.isci.2024.111662 · Cited by 3
Mehmood, A., Hakami, M. A., Ogaly, H. A., Subramaniyan, V., Khalid, A., & Wadood, A. (2025) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-025-04767-8 · Cited by 4
Patel, H. V., Smith, A. E., Chan, S., Gasendo, J. G., Jombik, A., Greer, J. E., Samantaray, T., Kessler, L. V., Mitra, A., Zhu, X., et al. (2026) · Cancer Research · doi:10.1158/0008-5472.can-25-2764 · Cited by 3
143D, a novel selective KRASG12C inhibitor exhibits potent antitumor activity in preclinical models
Xu, L., Zheng, S.-X., Mei, L., Yang, K., Wang, Y., Zhou, Q., Kong, X., Zheng, M.-Y., Jiang, H., & Xie, C. (2023) · Acta Pharmacologica Sinica · doi:10.1038/s41401-023-01053-2 · Cited by 4
Emerging Therapies in Kirsten Rat Sarcoma Virus (+) Non-Small-Cell Lung Cancer
Karachaliou, A., Kotteas, E. A., Fiste, O., & Syrigos, K. (2024) · Cancers · doi:10.3390/cancers16081447 · Cited by 3
Kirsten rat sarcoma inhibitors in clinical development against nonsmall cell lung cancer
Li, Y., Hu, L., & Xu, C. S. (2021) · Current Opinion in Oncology · doi:10.1097/cco.0000000000000808 · Cited by 3
Runx3 Restoration Regresses K-Ras-Activated Mouse Lung Cancers and Inhibits Recurrence
Lee, J.-Y., Lee, J.-W., Park, T.-G., Han, S.-H., Yoo, S.-Y., Jung, K.-M., Kim, D.-M., Lee, O.-J., Kim, D., Chi, X., et al. (2023) · Cells · doi:10.3390/cells12202438 · Cited by 3
Stitou, M., Koomen, J. M., Imbody, D. J., Liao, Y., Monastyrskyi, A., Rix, U., Duckett, D. R., Haura, E. B., & Karolak, A. M. (2024) · BJR|Artificial Intelligence · doi:10.1093/bjrai/ubae001 · Cited by 3
Song, Y., Wang, Y., Guan, A., Xue, J., Li, B., Huang, Z., Zheng, Z., Liang, N., Yang, Y., & Li, S. (2023) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2023.1132940 · Cited by 3
Filling in the GAPs in understanding RAS
Cox, A. D., & Der, C. J. (2021) · Science · doi:10.1126/science.abl3639 · Cited by 3
Thioredoxin Reductase 1 inhibition triggers ferroptosis in KRAS-independent lung cancersPreprint
Andreani, C., Bartolacci, C., Melegari, M., Sargentoni, N., Luciani, L., Marucci, A., Galeazzi, R., DeNicola, G. M., Kilgore, J. A., Williams, N. S., et al. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.07.25.666783 · Cited by 3
Meraz, I. M., Wu, S., Xu, Y., Gao, L., Feng, M., Ren, C., Song, R., Zhang, R., Wang, Q., Xi, Y., et al. (2025) · eLife · doi:10.7554/elife.106875.1 · Cited by 3
Bandi, D. S. R., Nagaraju, G. P., Sarvesh, S., Wang, J. W., Foote, J. B., Keeton, A. B., Chen, X., Ramírez‐Alcántara, V., Holmes, T., Akce, M., et al. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.02.11.705411 · Cited by 4
Tackling KRASG12C-mutated non-small-cell lung cancer: iteration and exploration
Luo, J., & Villaruz, L. C. (2024) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(24)00116-4 · Cited by 2
KRAS inhibitors in drug resistance and potential for combination therapy
Rathod, L. S., Sakle, N. S., & Mokale, S. N. (2024) · Tumori Journal · doi:10.1177/03008916241289206 · Cited by 3
Novel paradigms in KRAS targeting: Unveiling strategies to combat drug resistance
Luo, X., Zhou, F., Tang, Y., Liu, X., Xiao, R., Gu, M., Bai, J., Jiang, D., Yang, G., You, L., et al. (2025) · Chinese Medical Journal · doi:10.1097/cm9.0000000000003776 · Cited by 2
Targeting RAS-mutant cancer cells using a synthetic RAS-activated cancer killing system
Teng, F., Gao, Q., Li, Z., Cui, T., Tan, X., Ding, Y., Li, R., Li, B., Zhong, B., Miao, M., et al. (2025) · Trends in biotechnology · doi:10.1016/j.tibtech.2025.07.031 · Cited by 2
Driving Precision Medicine in Pancreatic Cancer With Molecular Genetics
Farooq, M., & Pishvaian, M. J. (2025) · Seminars in Radiation Oncology · doi:10.1016/j.semradonc.2025.08.004 · Cited by 2
Emerging Systemic Therapy Considerations for Pancreatic Cancer
Liang, K.-L., Guo, M. Z., & Zaidi, N. (2025) · Seminars in Radiation Oncology · doi:10.1016/j.semradonc.2025.07.006 · Cited by 2
He, D., Zhu, Y., Zhong, J., Cai, H., Li, Y., Zhuang, W., He, Y., Xu, Y., Fan, L., Fei, K., et al. (2025) · Journal of the National Cancer Center · doi:10.1016/j.jncc.2025.11.003 · Cited by 2
Deprivation of EGFR signal causes senolysis in PDAC with CDK4/6 inhibition
Zhang, Y., Kohno, S., Gao, K., Hasan, M., Baba, T., Zhang, Z., Sankoda, N., Yu, H., Pan, J., Gotoh, N., et al. (2025) · Cell Death and Differentiation · doi:10.1038/s41418-025-01634-0 · Cited by 2
An overview of KRAS-targeting therapies for colorectal cancer in phase I and II development
Chamseddine, S., Azmi, A. S., & Saif, M. W. (2025) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2025.2611395 · Cited by 2
Targeting HGF/MET and CXCL1/CXCR2 axes bypasses resistance to KRASG12C inhibitors in NSCLC
Cavazzoni, A., Mariano, M. P., Palladini, A., Digiacomo, G., Monica, S., Bonelli, M., Galetti, M., Pace, I., Roncarati, R., Giovannetti, E., et al. (2026) · Lung Cancer · doi:10.1016/j.lungcan.2026.108939 · Cited by 2
Placing purines in precision medicine: Targeting a metabolic reliance in KRAS-mutant tumors
Boni, L. D., Claridge, S. E., Nath, S., Tofani, K., Stein, B. D., Park, E., Steiner, S., Elemento, O., Pauli, C., & Hopkins, B. D. (2026) · iScience · doi:10.1016/j.isci.2026.114954 · Cited by 2
Targeting the H/KRAS α4-β6-α5 Allosteric Lobe with Macrocyclic Peptides
Trân, K., Lavoie, H., Wahhab, A., Garrido, D., Jo, C. H., Poupart, M.-A., Arya, T., Beautrait, A., Killoran, R. C., Dicaire-Leduc, C., et al. (2026) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.6c00078 · Cited by 2
From G12C To pan-RAS: The expanding therapeutic landscape of KRAS-mutant NSCLC
Canaslan, K., Başbınar, Y., & Öztop, İ. (2026) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2026.105344 · Cited by 2
Robb, R. N., Ackermann, S. E., Degan, S. E., Taylor, K. E., Yang, R. Y., Marler, A. Z., Calvert, V. S., Pierobon, M., Lyons, S. P., Barker, N. K., et al. (2026) · Cancer Research Communications · doi:10.1158/2767-9764.crc-25-0731 · Cited by 2
Targeting Distinct Cell-Cycle Nodes Overcomes RAS Inhibitor Resistance
Kumarasamy, V. M., Wang, J., Yau, E. H., Abel, E. V., Witkiewicz, A. K., & Knudsen, E. S. (2026) · Cancer Research · doi:10.1158/0008-5472.can-26-1315 · Cited by 2
Emerging pharmacology of targeted protein degraders
Barghout, S. H., & Eldeeb, M. A. (2025) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/j.jpet.2025.103694 · Cited by 2
Targeting Oncogenic Driver Mutations in Lung Cancer
Lee, M. H., Rous, F. A., Borczuk, A., Liu, S. V., Gadgeel, S. M., & Halmos, B. (2023) · Cambridge University Press eBooks · doi:10.1017/9781009336123 · Cited by 2
Sahu, P., Mitra, A., & Ganguly, A. (2024) · International review of cytology · doi:10.1016/bs.ircmb.2024.01.005 · Cited by 2
Matsubara, Y., Bando, H., Kotani, D., Kagawa, Y., Harada, K., Osumi, H., Izawa, N., Kawakami, T., Boku, S., Matsumoto, T., et al. (2024) · ESMO Gastrointestinal Oncology · doi:10.1016/j.esmogo.2024.100066 · Cited by 2
Fibroblasts Promote Resistance to KRAS Silencing in Colorectal Cancer Cells
Mendonça, S., Carvalho, P. D., Serra‐Roma, A., Oliveira, P., Ribeiro, A., Carvalho, J., Martins, F., Machado, A. L., Oliveira, M. J., & Velho, S. (2024) · Cancers · doi:10.3390/cancers16142595 · Cited by 2
Yin, L., Niu, T., Li, L., Yu, W. D., Han, B., Rehman, A., & Zeng, K. (2025) · Chinese Herbal Medicines · doi:10.1016/j.chmed.2025.01.001 · Cited by 2
Metadata
- Authors
- Tanaka, N., Lin, J. J., Li, C., Ryan, M. B., Zhang, J., Kiedrowski, L. A., Michel, A. G., Syed, M. U., Fella, K. A., Sakhi, M., Baiev, I., Juric, D., Gainor, J. F., Klempner, S. J., Lennerz, J. K., Siravegna, G., Bar-Peled, L., Hata, A. N., Heist, R. S., & Corcoran, R. B.
- Affiliations
- Harvard University (US)
- Guardant (United States) (US)
- Massachusetts General Hospital (US)
- 1Massachusetts General Hospital Cancer Center and Department of Medicine, Harvard Medical School, Boston, Massachusetts.
- Corresponding author
- Hata, Aaron N.
- Heist, Rebecca S.
- Corcoran, Ryan B.
- ORCID
- Venue
- Cancer Discovery
- Published
- 2021-04-06
- Volume
- 11
- Issue
- 8
- Pages
- 1913-1922
- ISSN
- 2159-8274 (ISSN-L)
- 2159-8290
- PMC
- PMC8338755
- OpenAlex
- W3142010099
- Cited by
- 527
- References
- 29
- Citations by year
- 2026: 85 · 2025: 100 · 2024: 124 · 2023: 91 · 2022: 86 · 2021: 41
- FWCI
- 26.89
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Cancer Discovery (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- Revolution Medicines (RM-018)
- Stand Up To Cancer—American Cancer Society Lung Cancer Dream Team Translational Research Grant (SU2C-AACR-DT17–15)
- NIH (R01-CA164273, 1F32CA250231–01)
- AACR (19–20–45-BARP)
- Damon Runyon (DRR-62–20)
- NIH NCI (R00 CA215249)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Kinase Regulation and GTPase Signaling
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Melanoma and MAPK Pathways
- Keywords
- KRAS G12C, acquired drug resistance, switch-II pocket, adagrasib, sotorasib, non-small cell lung cancer, NRAS, BRAF, MEK1, drug-protein binding
- MeSH terms
- Acetonitriles, Aged, Antineoplastic Agents, Carcinoma, Non-Small-Cell Lung, Female, Humans, Lung Neoplasms, Neoplasm Metastasis, Piperazines, Pyridines, Pyrimidines, Proto-Oncogene Proteins p21(ras), Drug Resistance, Neoplasm
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
